In breast cancer, recent findings also indicate that the loss of PTPN12 phosphatase function activates several oncogenic RTKs such as MET, PDGFRb, HER2, and EGFR [40,41,66], positioning PTPN12 as a master regulator of protein tyrosine kinases. The gene discussed is MET; the disease is breast carcinoma.